Contents:

Introduction to Datamonitor About Healthcare TABLE OF CONTENTS EXECUTIVE SUMMARY Report summary Introduction Patient potential in lung cancer Unmet needs in lung cancer Investors in lung cancer Class focus Future market leaders R&D opportunities in lung cancer DISEASE OVERVIEW Definition of lung cancer NSCLC SCLC Classification of lung cancer Disease type Staging for lung cancer Performance status Age at diagnosis Prognostic factors Classification of pipeline products Cytotoxic therapies: an overview Alkylating agents Antimetabolites Vinka alkaloids Other cytotoxics Angiogenesis inhibitors Immunotherapies Gene therapies Clinical endpoints in lung cancer Survival Toxicity Quality of life Response rates Multiple end points Unmet needs in lung cancer Extended disease-free survival Reduced toxicity Metastatic disease Second line therapy Older patients Screening Prevention LUNG CANCER PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in lung cancer Key R&D protocol strategies in lung cancer Key drug delivery strategies in lung cancer Key licensing strategies in lung cancer Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company DRUG ANALYSIS Cytotoxics Multitargeted antifolate (Alimta) Tirazone (tirapazamine) SPI-77 Troxacitabine Pivanex DA-125 XR5000 CP 358,774 Decitabine ILX-295501 DX-8951f Irofulven (MGI-114) Angiogenesis inhibitors Neovastat Prinomastat Marimastat SU5416 Iressa Immunotherapies Mitumomab rhuMAb-VEGF SRL 172 Recombinant interferon beta BLP25 Gene therapies ISIS 3521 SCH 58500 RPR/INGN 201 Genasense Others RSR13 Incel (biricodar) Key phase I development projects Research developments TheraFab NC381 Recently discontinued projects BMS 182751 BAY 12 9566 COMPARATIVE ANALYSIS Comparison by class Survival Toxicity Elderly patients Refractory/relapsed disease Marketing strength Comparative analysis of cytotoxics Comparison of disease-free survival in cytotoxics Comparison of toxicity in cytotoxics Comparison of cytotoxics in elderly patients Comparison of cytotoxics in refractory/relapsed disease Comparison of marketing strength in cytotoxics Comparative analysis of antiangiogenic agents Comparison of disease-free survival in antiangiogenic agents Comparison of toxicity in antiangiogenic agents Comparison of performance of antiangiogenic in elderly patients Comparison of antiangiogenic agents in refractory/relapsed disease Comparison of marketing strength in antiangiogenic agents Comparative analysis of immunotherapies Comparison of disease-free survival in immunotherapies Comparison of toxicity in immunotherapies Comparison of immunotherapies in elderly patients Comparison of immunotherapies in refractory/relapsed disease Comparison of marketing strength in immunotherapies FUTURE FOCUS IN LUNG CANCER Future trends in the incidence and prevalence of lung cancer Prospective drug launches in lung cancer Launch forecast methodology Forecast launches in lung cancer from 2000 to 2007 Market forecasts, 2000-2007 Forecast methodology Lung cancer market forecast, 2000-2007 Lung cancer drug class forecast, 2000- 2007 Key R&D product forecasts APPENDIX Clinical trial data bibliography Forecasting drug launches Global highest stage of development Reclassification of development phases List of tables List of figures